ADMA BiologicsADMA -2.05%68 Days Payable is 58.20 as of Mar. 2026, which is 12% above its 10-year median of 52.12. GuruFocus rates ADMA with a GF Score™ of 68/100 and a GF Value™ of $18.05 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 701 Biotechnology companies, ADMA Biologics ranks worse than 72.04% on this metric.
The historical rank and industry rank for ADMA Biologics's Days Payable or its related term are showing as below:
ADMA'
s Days Payable Range Over the Past 10 Years
Min: 31.15 Med: 52.12 Max: 133.5
Current: 43.42
During the past 13 years, ADMA Biologics's highest Days Payable was 133.50. The lowest was 31.15. And the median was 52.12.
ADMA's Days Payable is ranked worse than 72.04% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs ADMA: 43.42
ADMA Biologics's Days Payable
increased
from Mar. 2025 (34.68) to Mar. 2026 (58.20).
It may suggest that ADMA Biologicsdelayed paying its suppliers.
ADMA Biologics Days Payable Related Terms
ADMA Biologics Days Payable Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ADMA Biologics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Days Payable distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ADMA Biologics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a Days Payable of 58.20 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ADMA Biologics and its competitors. This is 12% above median its historical median of 52.12. Over the past decade, ADMA Biologics' Days Payable has ranged from 31.15 to 133.50. According to the industry distribution chart, ADMA Biologics ranks #505 out of 701 companies in the Biotechnology industry, placing it in the top 72%.
Is ADMA Biologics' Days Payable too high?
ADMA Biologics' current Days Payable of 58.20 is 12% above median its 10-year median of 52.12. Over the past 10 years, this metric has ranged from a low of 31.15 to a high of 133.50. The Biotechnology industry median Days Payable is 112.84. ADMA Biologics' value of 58.20 is 48.4% below this industry median. Based on the distribution chart, ADMA Biologics ranks #505 out of 701 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ADMA Biologics has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Days Payable compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #505 out of 701 companies for Days Payable. This places ADMA Biologics in the lower half of its industry. The industry median Days Payable is 112.84. ADMA Biologics' value of 58.20 is 48.4% below this benchmark. Historically, ADMA Biologics' own Days Payable has ranged from 31.15 to 133.50 over the past decade. While the company's 10-year median is 52.12 vs. the industry median of 112.84, ADMA Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Days Payable of 58.20 is 48.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Days Payable is 58.20, which is 12% above median its own 10-year median of 52.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.05, compared to a current price of $9.11 — trading 49.6% below its estimated fair value. The current Days Payable is 58.20, which is 12% above median its 10-year median of 52.12 and 48.4% below the Biotechnology industry median of 112.84. ADMA Biologics' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Days Payable is 58.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.11 is trading 49.6% below its estimated GF Value™ of $18.05.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Days Payable: 58.20 (12% above median its 10-year median of 52.12)
GF Value™: $18.05 vs. price of $9.11 (49.6% below fair value)
Industry Position: 48.4% below the Biotechnology median (#505 of 701)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
68GF Score
Get the complete analysis for ADMA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
